Drug intelligence / Profile preview

nigericin

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Not Typically Administered Clinically; Used In Vitro/in Vivo Research Settings.
01

Overview

Nigericin is a polyether ionophore antibiotic produced by the bacterium Streptomyces hygroscopicus. It acts primarily as an antiporter for protons (H+) and potassium ions (K+), facilitating their exchange across biological membranes. Nigericin can also transport lead ions (Pb2+). Its mechanism of action involves disrupting ion gradients, particularly in mitochondria, affecting ATPase activity and mitochondrial membrane potential. In eukaryotic cells, nigericin inhibits Golgi function and induces K+ efflux, which potently activates the NLRP3 inflammasome—a multiprotein complex involved in innate immune responses and inflammation. Historically used as an antibiotic against gram-positive bacteria, nigericin is now mainly utilized as a research tool to study ion transport and inflammasome activation[1][2][3][4][5].

Other names
polyetherin Aazalomycin Mhelixin C
02

Targets

Biological membraneNLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on nigericin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nigericin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call